In-transit melanoma: The role of alkylating-agent resistance in regional therapy

Journal of the American College of Surgeons

Volumn 199, Issue 3, 2004, Pages 419-427

  Grubbs, Elizabeth G ^a   Abdel Wahab, Omar ^a   Cheng, Tsung Yen ^a   Abdel Wahab, Zeinab ^a   Peterson, Bercedis ^a   Pruitt, Scott K ^a   Colvin, O Michael ^a   Friedman, Henry S ^a   Tyler, Douglas S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

glutathione; glutathione S transferase; GSH; GST; L PAM; L phenylalanine mustard; SC; subcutaneous

Indexed keywords

ALKYLATING AGENT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MELANOMA; MODEL; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SKIN; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE; TUMOR RECURRENCE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MELANOMA, EXPERIMENTAL; MELPHALAN; METABOLIC DETOXICATION, DRUG; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 3843098456     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2004.05.271     Document Type: Article

References (43)

1. Jemal A., Murray T., Samuals A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
2. Lingam M., Byrne D., Aitchison T., MacKie R. A single center's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer. 32:1996;1668-1673
3. McBride C., Sugarbaker E., Hickey R. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg. 182:1975;316-324
4. Franklin H., Schraffordt Koops H., Oldhoff J., et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol. 6:1988;701-708
5. Koops H., Voglini M., Sucius S., et al. Prophylactic isolated limb perfusion for localized high risk limb melanoma results of a multicenter randomized phase III trial. J Clin Oncol. 16:1998;2906-2912
6. Balch C. Cutaneous melanoma. 3rd ed:1998;Quality Medical Publishing, St. Louis, MO
7. Thompson J., Gianoustos M. Isolated limb perfusion for melanoma effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 16:1992;227-232
8. Lejeune F., Ghanem G. A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Research. 47:1987;639-643
9. Briele H., Djuric M., Jung D., et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 45:1985;1885-1889
10. Storm F., Morton D. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 15:1985;32-35
11. Di Filippo F., Calabro A., Giannarelli D., et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic aniblastic perfusion. Cancer. 63:1989;2551-2661
12. Skene A., Bulman A., Williams T., et al. Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg. 77:1990;765-767
13. Thompson J., Hunt J., Shannon K., Kam P. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 132:1997;903-907
14. Vrouenraets B., Hart G., Eggermont A., et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 188:1999;522-530
15. Taber S., Polk H. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol. 4:1997;440-445
16. van Geel A., van Wijk J., Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer. 63:1989;1092-1096
17. McClean S., Hill B.T. An overview of membrane, cytosolic, and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta. 1114:1992;107-127
18. Suzukake K., Vistica B., Vistica D. Resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol. 32:1983;165-167
19. Suzukake K., Petro B., Vistica D. Reduction in glutathione content of LPAM resistant cells confers drug sensitivity. Biochem Pharmacol. 31:1982;121-124
20. Green J., Vistica D., Young R., et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44:1984;5427-5431
21. Hayes J., Pulford D. The glutathione S-transferase supergene family regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 30:1995;445-600
22. Butler B., Clapper M., Tew K. Glutathione-S-transferase in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol. 31:1987;575-578
23. Robson C., Lewis A., Wolf C., et al. Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione-S-transferase activity. Cancer Res. 47:1987;6022-6027
24. Tietze F. Enzyme method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem. 27:1969;502-522
25. Griffith O. Determination of glutathione and glutathione-disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 106:1980;207-212
26. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254
27. Habig W., Pabst M., Jakoby W. Glutathione-S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 249:1974;7130-7139
28. Friedman H., Colvin O., Aisaka K., et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res. 50:1990;2455-2462
29. Ahmad S., Okine L., Le B., et al. Elevation of glutathione in phenylalanine mustard resistant murine L-1210 leukemia cell lines. J Biol Chem. 262:1987;15048-15053
30. Gupta V., Singh S., Ahmad M., et al. Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan. Biochem Pharmacol. 38:1989;1993-2000
31. Barranco S., Townsend C., Weintraub B., et al. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res. 50:1990;3614-3618
32. Medh R., Gupta V., Awasthi Y. Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism. Biochem Pharmacol. 42:1991;439-441
33. Buller A., Clapper M., Tew K. Glutathione-S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol. 31:1987;575-578
34. Cowan K., Batist G., Tupule A., et al. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance in xenobiotics in rats. Proc Natl Acad Sci USA. 83:1986;9328-9332
35. Moscow J., Fairchild C., Makken M., et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 48:1989;1422-1428
36. Dethmers J., Meister A. Glutathione export by human lymphoid cells depletion of glutathione by inhibition of its synthesis decreases its export and increases sensitivity to irradiation. Proc Natl Acad Sci USA. 78:1981;492-496
37. Kramer R., Greene K., Ahmad S., Vistica D. Chemosensitization of L-phenylalanine mustard by the thio-modulating agent buthionine sulfoximine. Cancer Res. 47:1987;1593-1597
38. O'Dwyer P., Hamilton T., Young R., et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine clinical and biochemical results. J Natl Cancer Inst. 84:1992;264-267
39. Skapek S., Colvin O., Griffith O., et al. Enhanced melphalan cytotoxicity following butathione sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res. 48:1988;2764-2767
40. Bolton M., Colvin O., Hilton J. Specificity of isoenzymes of murine hepatic glutathione S-transferase for the conjugation of glutathione with L-phenylalanine mustard. Cancer Res. 51:1991;2410-2415
41. Colvin O., Friedman H., Gamcsik M., et al. Role of glutathione in cellular resistance to alkylating agents. Advances in enzyme. Regulation. 33:1993;19-26
42. Rhodes T., Twentyman P. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Br J Cancer. 65:1992;684-690
43. Gupta V., Jani J., Jacobs S. Activity of melphalan in combination with glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol. 36:1995;13-19